Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 28;12(1):12.
doi: 10.3390/jpm12010012.

Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma

Julia Yu Fong Chang  1   2   3 , Chih-Huang Tseng  1   4   5 , Pei Hsuan Lu  1   2 , Yi-Ping Wang  1   2   3
Affiliations
Review

Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma

Julia Yu Fong Chang et al. J Pers Med. .

Abstract

New molecular tests and methods, in addition to morphology-based diagnosis, are widely used as a new standard of care in many tumors. "One-size-fits-all medicine" is now shifting to precision medicine. This review is intended to discuss the key steps toward to development of precision medicine and its implication in oral squamous cell carcinoma. The challenges and opportunities of precision medicine in oral cancer will be sequentially discussed based on the four steps of precision medicine: identification/detection, diagnosis, treatment and monitoring.

Keywords: oral squamous cell carcinoma; personalized medicine; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic illustration of key steps of precision medicine.
Figure 2
Figure 2
Schematic illustration of the transition from traditional medicine to precision medicine and future personalized medicine.
Figure 3
Figure 3
Comparison of the most recent treatment guidelines from The National Comprehensive Cancer Network® (NCCN®) for non-small cell lung cancers and head and neck cancers.
Figure 4
Figure 4
Proposed targeted therapy for head and neck cancers based on the identified druggable targets.
Figure 5
Figure 5
Timeline of major discoveries and related therapeutic approaches in head and neck squamous cell carcinoma. (R/M: recurrent/metastatic, HNSCC: head neck squamous cell carcinoma).
Figure 6
Figure 6
Schematic illustration of precision medicine in oral cancer in the future. PDX, Patient-Derived Tumor Xenograft.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Su S.Y., Chen W.T., Chiang C.J., Yang Y.W., Lee W.C. Oral cancer incidence rates from 1997 to 2016 among men in Taiwan: Association between birth cohort trends and betel nut consumption. Oral Oncol. 2020;107:104798. doi: 10.1016/j.oraloncology.2020.104798. - DOI - PubMed
    1. Chow L.Q.M. Head and Neck Cancer. N. Engl. J. Med. 2020;382:60–72. doi: 10.1056/NEJMra1715715. - DOI - PubMed
    1. Margalit D.N., Sacco A.G., Cooper J.S., Ridge J.A., Bakst R.L., Beadle B.M., Beitler J.J., Chang S.S., Chen A.M., Galloway T.J., et al. Systematic review of postoperative therapy for resected squamous cell carcinoma of the head and neck: Executive summary of the American Radium Society appropriate use criteria. Head Neck. 2021;43:367–391. doi: 10.1002/hed.26490. - DOI - PMC - PubMed
    1. Sacco A.G., Chen R., Worden F.P., Wong D.J.L., Adkins D., Swiecicki P., Chai-Ho W., Oppelt P., Ghosh D., Bykowski J., et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: An open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22:883–892. doi: 10.1016/S1470-2045(21)00136-4. - DOI - PubMed

LinkOut - more resources